knowledge -WSS

knowledge

author：leisure time 2025-10-02 05:38:22 - browse：27176

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Why we need to separate burnout from moral injury in health care

hotspot

WSS

Listen: Wegovy in the brain & pivotal Alzheimer's data

Listen: Wegovy in the brain & pivotal Alzheimer's data

Disclosing genetic information: not as worrisome as once feared

CDC concerned about possible undetected monkeypox spread in U.K.

Cloning humans is technically possible. It's curious no one has tried

Group opposing PBM reform sets lobbying record

explore

knowledge

Wikipedia

Heart attack and stroke risk calculators need revising

Weight bias in eating disorder treatment complicated by new weight loss drugs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The science behind Janet Jackson's pregnancy at 49

What does generative AI mean for health care? We asked experts

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Moonlake's readout produced a cash windfall. Risks remain

Google and Epic fight stronger regulation of AI in health care

knowledge

Startup Neumora takes a novel depression drug to Phase 3

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Sanders adds drug shortage policies to pandemic preparedness bill

With FDA staff opposed to Sarepta therapy, top official intervened

Disclosing genetic information: not as worrisome as once feared

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

entertainment

focus

hotspot

knowledge